News
Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...
The tissue factor pathway inhibitor (TFPI) antagonist, given as a subcutaneous injection, has been cleared to prevent or reduce bleeding episodes in patients aged 12 years and older with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results